Henan Taloph Pharmaceutical Stock Co Ltd (600222) - Total Liabilities
Based on the latest financial reports, Henan Taloph Pharmaceutical Stock Co Ltd (600222) has total liabilities worth CN¥2.01 Billion CNY (≈ $294.28 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Henan Taloph Pharmaceutical Stock Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Henan Taloph Pharmaceutical Stock Co Ltd - Total Liabilities Trend (1996–2025)
This chart illustrates how Henan Taloph Pharmaceutical Stock Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Henan Taloph Pharmaceutical Stock Co Ltd (600222) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Henan Taloph Pharmaceutical Stock Co Ltd Competitors by Total Liabilities
The table below lists competitors of Henan Taloph Pharmaceutical Stock Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Merry Electronics Co Ltd
TW:2439
|
Taiwan | NT$22.64 Billion |
|
Semen Indonesia Persero Tbk
JK:SMGR
|
Indonesia | Rp27.67 Trillion |
|
Fundamenta Real Estate AG
SW:FREN
|
Switzerland | CHF712.42 Million |
|
PTC India Limited
NSE:PTC
|
India | Rs55.72 Billion |
|
Red River Bancshares Inc
NASDAQ:RRBI
|
USA | $2.97 Billion |
|
Beijing Science Sun Pharmaceutical Co Ltd
SHE:300485
|
China | CN¥171.26 Million |
|
Rosenbauer International AG
VI:ROS
|
Austria | €1.02 Billion |
|
Anhui Coreach Technology Co Ltd
SHE:002983
|
China | CN¥563.08 Million |
Liability Composition Analysis (1996–2025)
This chart breaks down Henan Taloph Pharmaceutical Stock Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Henan Taloph Pharmaceutical Stock Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Henan Taloph Pharmaceutical Stock Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Henan Taloph Pharmaceutical Stock Co Ltd (1996–2025)
The table below shows the annual total liabilities of Henan Taloph Pharmaceutical Stock Co Ltd from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.98 Billion ≈ $289.59 Million |
+6.20% |
| 2024-12-31 | CN¥1.86 Billion ≈ $272.69 Million |
-4.60% |
| 2023-12-31 | CN¥1.95 Billion ≈ $285.85 Million |
-1.64% |
| 2022-12-31 | CN¥1.99 Billion ≈ $290.63 Million |
-1.00% |
| 2021-12-31 | CN¥2.01 Billion ≈ $293.56 Million |
+7.93% |
| 2020-12-31 | CN¥1.86 Billion ≈ $272.00 Million |
+30.20% |
| 2019-12-31 | CN¥1.43 Billion ≈ $208.91 Million |
-1.14% |
| 2018-12-31 | CN¥1.44 Billion ≈ $211.32 Million |
+11.09% |
| 2017-12-31 | CN¥1.30 Billion ≈ $190.22 Million |
+12.95% |
| 2016-12-31 | CN¥1.15 Billion ≈ $168.41 Million |
+0.94% |
| 2015-12-31 | CN¥1.14 Billion ≈ $166.84 Million |
+3.13% |
| 2014-12-31 | CN¥1.11 Billion ≈ $161.78 Million |
+28.37% |
| 2013-12-31 | CN¥861.22 Million ≈ $126.02 Million |
-5.66% |
| 2012-12-31 | CN¥912.93 Million ≈ $133.59 Million |
+9.82% |
| 2011-12-31 | CN¥831.28 Million ≈ $121.64 Million |
+29.50% |
| 2010-12-31 | CN¥641.92 Million ≈ $93.93 Million |
+26.83% |
| 2009-12-31 | CN¥506.12 Million ≈ $74.06 Million |
+32.69% |
| 2008-12-31 | CN¥381.43 Million ≈ $55.82 Million |
+17.98% |
| 2007-12-31 | CN¥323.29 Million ≈ $47.31 Million |
+0.33% |
| 2006-12-31 | CN¥322.24 Million ≈ $47.15 Million |
+15.63% |
| 2005-12-31 | CN¥278.70 Million ≈ $40.78 Million |
-1.67% |
| 2004-12-31 | CN¥283.44 Million ≈ $41.48 Million |
+5.62% |
| 2003-12-31 | CN¥268.36 Million ≈ $39.27 Million |
+1.38% |
| 2002-12-31 | CN¥264.70 Million ≈ $38.73 Million |
+28.45% |
| 2001-12-31 | CN¥206.07 Million ≈ $30.15 Million |
+26.85% |
| 2000-12-31 | CN¥162.45 Million ≈ $23.77 Million |
+7.51% |
| 1999-12-31 | CN¥151.10 Million ≈ $22.11 Million |
-8.31% |
| 1998-12-31 | CN¥164.79 Million ≈ $24.11 Million |
+17.47% |
| 1997-12-31 | CN¥140.28 Million ≈ $20.53 Million |
+0.04% |
| 1996-12-31 | CN¥140.23 Million ≈ $20.52 Million |
-- |
About Henan Taloph Pharmaceutical Stock Co Ltd
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chew… Read more